Breast cancer therapy doesn't increase risk of COVID-19 infection, death, study finds

Breast cancer patients receiving chemotherapy had about the same risk of contracting COVID-19 as those taking cancer drugs that don't weaken the immune system, according to a study led by NYU Langone Health researchers set to be presented June 4 at the 2021 American Society of Clinical Oncology's 2021 Annual Meeting. 

Researchers analyzed the medical records of more than 3,000 breast cancer patients who received care at the New York City-based health system's Perlmutter Cancer Center from February to May 2020. They compared those who received cytotoxic, or cell-killing, chemotherapy, which can weaken the body's immune system, to those who received other cancer drugs.  

Just 2 percent of patients, or 64 people, became infected with COVID-19. Of those, 10 died, which researchers said was expected, regardless of cancer, indicating that breast cancer treatment did not raise the risk of dying from COVID-19. 

"Our results show that patients can safely receive breast cancer therapy, including chemotherapy, during the pandemic," said Douglas Marks, MD, lead study investigator and medical oncologist at Perlmutter Cancer Center. 

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars